Pharmaceutical Executive
Croatia's Pliva Pharmaceuticals is the first eastern European pharma company to make a US acquisition. Pliva paid $153 million for New Jersey-based Sobel Holdings,
Croatia's Pliva Pharmaceuticals is the first eastern European pharma company to make a US acquisition. Pliva paid $153 million for New Jersey-based Sobel Holdings, which owns Sidmak, a generics maker, and Odyssey, a specialty brand-name pharma company with products such as Urecholine (bethanechol) for non-obstructive urinary retention; Vivactil (protryptylline) and Surmontil (trimipramine) for depression; Antabuse (disulfiram) for alcohol abuse; Nystatin vaginal tablets (for candidiasis); and Custodol HTK solution for the preservation of donor organs.
In addition to the company's product rights and trademarks, the deal gives Pliva an established US distribution network and a product development and manufacturing plant in East Hanover, New Jersey.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.